To assess whether targeting PRDX2 in hepatocytes may be a therapeutic approach to prevent HCC in MASH, we performed a Prdx2 KD within therapeutic windows after MASH development. Here, PRDX2 is linked to metabolic dysfunction-associated steatohepatitis.